Outsourcing global clinical
& medical engagement for accelerated drug approval
& acceptance
AnswerY™, an AI-driven, HIPAA-compliant platform of prescriber-patient conversations that drives next-best actions
Outsourcing global clinical
& medical engagement for accelerated drug approval
& acceptance
AnswerY™, an AI-driven, HIPAA-compliant platform of prescriber-patient conversations that drives next-best actions
No image found.
Pharma marketers wear many hats, including developing strategic plans, building the top of the sales funnel, and designing promotional materials. To excel in any—or all—of these areas, understanding your audience, the prescriber, is essential. Yet, many marketers still wrestle with a fundamental question: What drives doctors to make the treatment decisions they do?
Traditional primary market research (PMR) in pharma offers some answers—through surveys, focus groups, or advisory boards. But they’re snapshots in time, not to mention often slow and costly. PMR studies often recruit from the same prescriber pools and therefore miss much of the nuance and humanity that can be found in real clinical decisions.
That’s where AI is rewriting the playbook. Amplity AnswerY™, our HIPAA-compliant, AI-powered platform, listens to the real world—literally. By analyzing tens of millions of physician–patient conversations, it surfaces the context, emotion, and reasoning behind treatment choices. For pharma marketing teams, this means direct access to the “why” behind healthcare provider (HCP) behavior—no guesswork required.
“AnswerY lets you be a fly on the wall,” says Amplity Chief Marketing Officer Janet Hughes. “You hear how patients describe symptoms, how physicians weigh options, and how treatment decisions get made—in their own words.”
Here’s an example record, straight from AnswerY:
This “inside intel” is a game-changer. It’s no longer about speculating why an HCP changed a treatment plan—you know. And this clarity can immediately shape smarter marketing strategies.
The difference with AnswerY is immediacy. Traditional PMR tells you what happened—but it’s retrospective, often outdated by the time you get it. AnswerY reveals the why behind decisions in real time, analyzing over a million new transcripts every month. Instead of reacting to last quarter’s market trends, your team can stay current with evolving HCP thinking, right now.
Even better, AnswerY delivers intel at scale while cutting pharma’s primary market research costs by up to 65%. Because it’s built on natural, unfiltered language— not pre-set prompts or rigid survey formats — you can see how HCPs actually talk about side effects, switch decisions, treatment barriers, and more. “It’s not just what happened—it’s why it happened,” Hughes explains. “That level of context changes how you approach strategy.”
Plus, with AnswerY, there’s no time or money wasted on recruiting participants for PMR. You can just search the platform to find the exact type of doctors you’re looking for—based on what conditions they treat, their expertise, or whatever criteria you need. And the best part? Because the AnswerY platform is made up of HIPAA-compliant, preexisting, unbiased insights from HCPs, you don’t need to pay out honorariums, so you’re saving money as well.
Advisory boards are valuable—but they’re narrow, slow, and scheduled. AnswerY offers scale, speed, and spontaneity. Instead of waiting weeks for a handful of opinions, teams can tap into thousands of HCP voices on demand—tracking sentiment shifts, validating assumptions, or stress-testing new ideas. “Ad boards give you a few voices,” Hughes says. “AnswerY gives you thousands. And that’s pretty powerful for a pharma marketer.”
AnswerY isn’t meant to replace ad boards, quant studies, claims data, or panels. Rather it’s designed to get you more for your investments by making these events and assets much more actionable. For example, conducting a sentiment analysis prior to an advisory board meeting equips marketers and researchers with a clearer understanding of recent objections and misconceptions, enabling them to develop more precise and detailed questionnaires. Alternatively, when recruiting for an HCP panel, marketers can search for the exact profile of physicians who will be most valuable when producing certain types of messaging.
“These are the types of next-level marketing strategies that aren’t possible when your teams only rely on structured data,” says Hughes. “AnswerY isn’t trying to out-volume quant studies. Instead, it’s bringing an entirely new set of insights that add clarity, context, and speed while also reducing costs. The end result is smarter and highly tailored commercial messaging rooted in real-world information.”
To get a better idea of what we mean, let’s compare pharma’s traditional primary market research methods to what AnswerY brings to the table.
Simply put, AnswerY redefines primary market research in pharma by delivering real-time insights that other datasets can’t and gives pharma marketers a distinct edge in a competitive market.
Even with all its advanced AI capabilities, AnswerY doesn’t leave you to figure it out alone. Every client works with a dedicated customer success manager and data science team to help shape questions, validate outputs, and turn findings into actionable insights.
“With so much data, it’s easy to feel overwhelmed,” Hughes acknowledges. “Our team helps you identify consistent patterns and meaningful barriers—so you can act faster, with clarity.”
Pharma is evolving—and staying relevant means listening better, being nimble, and understanding more. With AnswerY, pharma marketing teams can keep pace with the market, not behind it, and put the human voice back at the center of decision-making.
For pharma marketing teams looking to do more with less—and do it smarter—AnswerY is your answer to understanding what docs are really thinking.
Ready for a demo? Contact us to see how AnswerY drives pharma’s next best actions.
